Home » Archive

Xconomy

News, Syndication, Xconomy »

What Was Hyped, and What Fell Out of Favor, This Year in Biotech

Posted by sandiegobiotech December 16th, 2013 .
No Comments

Every year, Science magazine profiles its “Breakthrough of the Year.” People get excited. But what many readers don’t fully appreciate is that these discoveries—at least in…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

How Nelson Mandela Inspired Me to Fight Infectious Disease

Posted by sandiegobiotech December 16th, 2013 .
No Comments

[Editor's Note: Alan Aderem is a former political activist from South Africa who now serves as the President of Seattle BioMed, a research institute that focuses on global infectious diseases.] My…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Orexigen, Accelrys, Otonomy, & More

Posted by sandiegobiotech December 13th, 2013 .
No Comments

Drug development and deals continued apace as the Christmas holiday draws near. Here’s the latest in San Diego’s life sciences news. —-Orexigen Therapeutics (NASDAQ: OREX) said it has…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

U.S. IPO Activity in 2013 on Track for Highest Level in 9 Years

Posted by sandiegobiotech December 11th, 2013 .
No Comments

As the IPO counter continues to roll, the EY accounting firm says it estimates 2013 will ring up a total of 222 U.S. IPOs (or maybe 223), with cumulative proceeds generating a total of about $59.7…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Accelrys Acquires Irish Software Developer Qumas for $50M

Posted by sandiegobiotech December 10th, 2013 .
No Comments

San Diego scientific software developer Accelrys (NASDAQ: ACCL) says it has paid about $50 million in cash to acquire Qumas, an Irish specialist in compliance and quality management software. The…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

How Do You Want to Spend the Next Four Years of Your Life?

Posted by sandiegobiotech December 9th, 2013 .
No Comments

As our Lean LaunchPad for Life Sciences class winds down, a good number of the 26 teams are trying to figure out whether they should go forward to turn their class project into a business. Given that…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Layoffs Hit Optimer Following Cubist Buyout

Posted by sandiegobiotech December 6th, 2013 .
No Comments

Cubist Pharmaceuticals may have added some punch to its antibiotics portfolio by buying Optimer Pharmaceuticals a few months ago, but as is often the case with M&A deals, the buyout is also…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

FDA’s Culture Is Genetically Dominant Over 23andMe’s Business Model

Posted by sandiegobiotech December 5th, 2013 .
No Comments

I’ve been following the 23andMe saga with dread and fascination and frustration since it hit in late November. If you’re not up to date, David Dobbs has the canonical collection of stories to get you…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

San Diego’s Telephus Seeks $5M to Advance Anti-Infective Antibody

Posted by sandiegobiotech December 4th, 2013 .
No Comments

According to Greek mythology, “the wound that would not heal” was inflicted by the intemperate warrior Achilles when he fell upon Telephus, son of Hercules, after invading an allied kingdom in the…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Modern Day Scrooges Are Ruining Our Health Care System

Posted by sandiegobiotech December 3rd, 2013 .
No Comments

More than a 150 years ago Charles Dickens’ A Christmas Carol introduced the character Ebenezer Scrooge, who was the embodiment of greed, “tight-fisted…. a squeezing, wrenching, grasping, scraping,…

[[Click headline to continue reading.]]

More...